Ergebnis der Suchanfrage nach Therapie
Inhalte
- Kategorie:
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Intelligent algorithms for movement apps: with LTech, the Lindera Software Development Kit, Berlin-based health tech company Lindera brings innovation and AI technology to the fitness industry
mehrSysmex Inostics presents data at ASCO
Baltimore, MD (ots) - Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated SafeSEQ NGS HPV16/18 liquid biopsy assay, is highly effective for measuring HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial. Sysmex Inostics, Inc., a global leader in the liquid biopsy revolution for oncology, is presenting the poster ...
mehrInvestment breakthrough for BrainRepair UG start-up – Stem cell treatment for newborns / Dr. Metin Colpan, founder of Nasdaq listed Qiagen N.V. acquired 5% of BrainRepair UG shares worth EUR 15M
mehrTechnische Universität München
Neutrons show a connection between depression and lithium concentration in the brain
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36683/ High resolution images: https://mediatum.ub.tum.de/1612340 NEWS RELEASE Making the gray cells happy Neutrons show a connection between depression and ...
mehr- 3
High-tech prosthesis for enhanced safety: New Kenevo knee joint available
mehr Technische Universität München
Four ERC Advanced Grants for TUM scientists
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36588/ NEWS RELEASE EU funding for cutting-edge research Four ERC Advanced Grants for TUM scientists Artificial viruses made with DNA. The human lung as a computer model. A new approach to research on diseases ...
mehr- 2
Lindis Biotech develops immunotherapy against bladder cancer
Ein Dokumentmehr Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients
Baltimore, MD, USA (ots) - Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster “Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer (NSCLC) patients” at the 112th Annual Meeting of the American Association for Cancer ...
mehrSemdor Pharma adds Global Pharmaceutical Executive Rolf Hoffmann to its Board of Directors
Cologne (ots) - 30-year pharma veteran Rolf Hoffmann, formerly senior global executive at Amgen and Eli Lilly, joins Semdor Pharma as investor and commercial expert. Semdor Pharma Group announced today that it has added Rolf Hoffmann, a seasoned global pharma executive and advisor, to its Board of Directors, as well as an investor in the company. Mr. Hoffmann ...
mehrSocial Stigma Burdens Innovative Lung Cancer-Therapies, Study Says
Social Stigma Burdens Innovative Lung Cancer-Therapies, Study Says Social stigma towards diseases such as lung cancer can hinder patients to seek treatment and, as a consequence, negatively affects the diffusion of innovative therapies, according to a recently published study. “Lung cancer carries a unique social stigma due to its association with cigarette smoking, and hence is often seen as a smoker’s disease, ...
mehrFirst pocket inhaler for Covid-19 and other viral mutations
Buochs (ots) - DG-Nika AG – a new approach to therapy & proactive protection from the pandemic The corona pandemic continues to pose a global threat: To date, it has been possible to vaccinate only a small fraction of the total population. On top of that, there is acute danger from mutations of this virus. Against this backdrop, the DG-Nika AG research team has developed a solution for a new approach to protecting the ...
mehr- 2
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
mehr - 2
A higher omega-3 level apparently protects from dying from COVID-19
Ein Dokumentmehr - 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
Ein Dokumentmehr Merger: Newly-formed Semdor Pharma Group becomes one of Europe's leading pharmaceutical companies for narcotics and medical cannabis
mehrEleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member
Freiburg (ots) - Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to ...
mehrTechnische Universität München
Breathing rate predicts therapeutic benefits for heart patients
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36385/ NEWS RELEASE Discovering a forgotten biosignal Breathing rate predicts therapeutic benefits for heart patients Conditions causing arrhythmia are among ...
mehrSysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based, high-sensitivity molecular testing for oncology, is presenting the poster "Ultrasensitive Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML) Using a Targeted Next Generation Sequencing (NGS) Panel" at ...
mehrKOPIE VON: Commemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups
Enclosed we send you the news of the day about the IZB. We would be pleased if you would consider the message in your news coverage. If you have any question ...
Ein DokumentmehrSwiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine
mehrFollow your gut: How farms protect from childhood asthma
mehrEvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs)
Salzburg/Melide(CH) (ots) - Swiss Biotech EvoBiotiX SA today announced a multi-year collaboration with Boehringer Ingelheim in the field of naturally derived EVs. A significant part of this program will fund research of the drug delivery potential of naturally derived EVs in the group of Prof. Meisner-Kober at the ...
mehrTechnische Universität München
Coronavirus: door opener facilates cell entry
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36263/ NEWS RELEASE How the virus enters the cell Coronavirus: Neuropilin-1 could open the door to the inside of the cell The protein neuropilin-1 facilitates SARS CoV-2 cell entry. A research team including ...
mehr- 4
Novel medical imaging approach unlocks potential for improved diagnosis and interventions
mehr Regulatory breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns /EMA Orphan Drug Designation is followed by agreement on Paediatric Investigation Plan
mehr- 4
"Honey, I shrunk the detector": Researchers have developed the world's smallest ultrasound detector
mehr Sysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating cell-free tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study investigating the utility of cfDNA-based markers using the highly sensitive OncoBEAM RAS assay, an enhanced ...
mehrSysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA (ctDNA) of colorectal cancer (CRC) patients undergoing anti-EGFR ...
mehrKOPIE VON: Inspirational talks form SIRION Biotech, CLS Behring and the German Accelerator at the 13th Biotech Press Lounge at the IZB
Ein Dokumentmehr